Pharmaceutical Safety Review • High Interaction Classification

Clinical Head-to-Head Prescription Drug Interactions & CYP450 Profile

Systematic analysis of cytochrome P450 enzyme metabolism, renal clearance competition, and clinical contraindications.

Absolute Clinical Contraindications

  • Medullary thyroid carcinoma family history
  • MEN-2 syndrome
  • Severe pancreatitis history

Reported Clinical Adverse Events

  • Nausea (22%)
  • Diarrhea (17%)
  • Constipation (14%)
  • Vomiting (9%)

Hepatic Cytochrome P450 (CYP) & Transporter Pathways

Compounds that modulate CYP3A4, CYP2D6, or P-glycoprotein (P-gp) can alter the bioavailability of concurrent medications including statins, anticoagulants, immunosuppressants, and blood pressure therapies:

  • CYP3A4 Substrate / Inhibitor: Potential competition with oral medications metabolized through hepatic CYP3A4 pathways.
  • Gastrointestinal Transit Modulation: GLP-1 receptor agonists and delayed-release botanicals slow gastric emptying, which may delay Tmax for orally administered therapeutics.
  • Pharmacokinetic Half-Life Clearance: Systemic clearance requires approximately 5 elimination half-lives (4 – 6 hours).

Protocol Audit Links for Clinical Head-to-Head

← Return to Clinical Head-to-Head Monograph Calculate Weight Dosage Table → Launch Full Multi-Drug Interaction Checker →